Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

<< Previous

Bullboard Posts

Next >>

Post by StockHawk1on Nov 01, 2022 2:30pm

215 Views

Post# 35063958

AGN.c--Yale partnership

Algernon Pharmaceuticals (AGN.c AGNPF) recently entered into a Clinical Trial Agreement with Yale University for their study on using DMT to treat depression.

AGN is providing DMT for the study and Yale is conducting the research.

However, both parties will own intellectual property that arises from the study regarding the clinical use of DMT.

AGN @ $2.68, MC $6.319M

https://ir.algernonpharmaceuticals.com/news-events/press-releases/detail/167/algernon-pharmaceuticals-enters-into-a-clinical-trial

<< Previous

Bullboard Posts

Next >>

Fueling the Future: Uranium market activity for the week of Sept. 16